Register Login

BRIDGEBIO PHARMA, INC. (BBIO)

Director Cook Jennifer E. 🟡 adjusted position in 30.1K shares (3 derivative) of BridgeBio Pharma, Inc. (BBIO) at $70.00 ($4.0M) Transaction Date: Jun 22, 2026 | Filing ID: 000636

Full text
Register to leave comments
  • News bot June 24, 2026, 10:07 p.m.

    🔍 Cook Jennifer E. (Director)

    Company: BridgeBio Pharma, Inc. (BBIO)

    Report Date: 2026-06-22

    Transaction Summary:

    • Total transactions: 8
    • Derivative instruments: 3
    • Holdings reported: 0
    • Total shares acquired: 46,434
    • Total shares sold: 76,530

    Detailed Transactions and Holdings:

    • Acquired 3,990 shares of Common Stock (Direct)
      Date: 2026-06-22 | Code: A | equity_swap_involved: 0 | shares_owned_after: 10,579.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 2,196 shares of Common Stock at $68.57 per share (Direct)
      Date: 2026-06-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,383.00 | transaction_form_type: 4 | Footnotes: F3
    • Acquired 20,000 shares of Common Stock at $8.45 per share (Direct)
      Date: 2026-06-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 28,383.00 | transaction_form_type: 4 | Footnotes: F3
    • Acquired 17,167 shares of Common Stock at $16.75 per share (Direct)
      Date: 2026-06-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,550.00 | transaction_form_type: 4 | Footnotes: F3
    • Sold 37,167 shares of Common Stock at $70.0 per share (Direct)
      Date: 2026-06-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,383.00 | transaction_form_type: 4 | Footnotes: F3
    • Acquired 5,277 shares of Stock Option (Right to Buy) at $68.92 per share (Derivative)
      Date: 2026-06-22 | Code: A | Expires: 2036-06-21 | equity_swap_involved: 0 | shares_owned_after: 5,277.00 | transaction_form_type: 4 | Footnotes: F4
    • Sold 20,000 shares of Stock Option (Right to Buy) at $8.45 per share (Derivative)
      Date: 2026-06-24 | Code: M | Expires: 2032-06-22 | equity_swap_involved: 0 | shares_owned_after: 19,000.00 | transaction_form_type: 4 | Footnotes: F3, F5
    • Sold 17,167 shares of Stock Option (Right to Buy) at $16.75 per share (Derivative)
      Date: 2026-06-24 | Code: M | Expires: 2033-06-21 | equity_swap_involved: 0 | shares_owned_after: 17,167.00 | transaction_form_type: 4 | Footnotes: F3, F6

    Footnotes:

    • F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
    • F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
    • F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
    • F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
    • F5: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
    • F6: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Search

News categories